Navigation Links
OvaGene Oncology Joins The Gynecologic Oncology Group (GOG) Industry Collaboration Team to Advance Gynecologic Cancer Research
Date:8/4/2010

IRVINE, Calif., Aug. 4 /PRNewswire/ -- OvaGene Oncology Inc., a biotechnology company specializing in the development and commercialization of personalized DNA-based diagnostics for gynecologic cancer, is pleased to announce their partnership with The Gynecologic Oncology Group (GOG) through the Industry Collaboration Team (ICT) program.  By becoming a member of the ICT, OvaGene Oncology demonstrates its commitment to building a strong partnership with the GOG research groups, namely medical centers, universities, and pharmaceutical companies dedicated to advancing the scientific and clinical knowledge of gynecologic cancers.  

OvaGene's mission to improve the quality of life and survival for gynecologic cancer patients is further enhanced by joining this select group.  The Industry Collaboration Team has a limited membership and OvaGene is honored to have been given an opportunity to become a member. By joining the ICT program, OvaGene will gain direct access to oncology leaders and key decision makers in the field gynecologic oncology.  This will facilitate direct communication with the cancer treating physicians about OvaGene's products and diagnostic research capabilities. The valuable feedback provided can help accelerate the development of OvaGene's product pipeline by allowing the company to identify and address unmet clinical needs.

"We are very pleased to be an ICT member," said William Ricketts, Ph.D., Chief Scientific Officer for OvaGene.  "The GOG has one of the largest archived and annotated gynecologic tumor banks.  It is a privilege to be given the opportunity to collaborate with the GOG as a member of the ICT and potentially on studies focused to discover and validate new molecular diagnostics. This will help us bring clinically useful tests to market for improved patient care and outcome."  

Dr. Neil Finkler, M.D., Chief Medical Officer for OvaGene stated, "We are very enthusiastic about this collaboration. The ability to run our clinical studies on archived tissues from the GOG, as well as future prospective trials, adds an additional level of validation and scientific review to our studies that will ultimately improve the quality of our product offerings leading to improved patient care."

About OvaGene Oncology

OvaGene Oncology is a molecular diagnostics company, located in Orange County California, dedicated to improving cancer care and outcomes for gynecologic cancer patients through the development of novel gene-based assays.  The company plans to offer proprietary and non-proprietary molecular diagnostic assays to assist physicians in the prognosis of gynecologic cancers as well as therapy selection, including radiation and chemotherapy.  There are over 11,000 cases of cervical cancer, 25,000 cases of ovarian cancer and 42,000 cases of endometrial cancer diagnosed each year in the United States.  The total market for OvaGene's genomic assays is over 80,000 gynecologic cancer cases diagnosed annually. Please visit our website at www.ovagene.com for more information about our company.

About The Gynecologic Oncology Group

The Gynecologic Oncology Group ("GOG") is a national organization dedicated to clinical research in the field of gynecologic cancer. It is one of the cooperative clinical trial research groups funded by the National Cancer Institute (NCI). The purpose and mission of the GOG is to improve and expand the treatment of gynecologic cancer. These goals are met through an exchange of information on programs of study, teaching methods and research activities among gynecologic oncologists, medical oncologists, radiation oncologists, nurse oncologists, pathologists, and basic scientists.  Visit www.gog.org for more details.


'/>"/>
SOURCE OvaGene Oncology Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OvaGene Oncology Opens New Innovative Gynecologic Cancer Laboratory and Research Facility
2. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
3. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
6. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
7. University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites
8. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
9. Pharsight Uses FDA Disease Model to Support Oncology Drug Development
10. US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium
11. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 27, 2017 FinancialBuzz.com News Commentary  ... Based on New Frontier Data,s ... where cannabis is legal will generate $655 million in taxes on ... cannabis specific taxes, such as Washington State,s ... earned from state sales taxes that are applied on all retail ...
(Date:3/27/2017)... March 27, 2017 BioLineRx Ltd. (NASDAQ/TASE: ... announced today that AGI-134, an immunotherapy for the treatment of ... Ltd., will be featured at the upcoming American Association ... Washington, DC to be held on April 1-5, ... ...
(Date:3/27/2017)... 2017   Pulmatrix, Inc . (NASDAQ: PULM), a clinical ... pulmonary diseases, today announced that it has added two experts ... asthma to its Scientific Advisory Board . ... B. Moss , MD, former chief of the Pediatric Pulmonary ... Center at Stanford University, and David ...
Breaking Medicine Technology:
(Date:3/27/2017)... Cranbury, NJ (PRWEB) , ... March 27, 2017 ... ... publication of cutting-edge news, research and conference coverage on veterinary medicine, announces the ... The inaugural issue will be packaged with the April edition of American Veterinarian™. ...
(Date:3/27/2017)... Farmingdale, NY (PRWEB) , ... March 27, 2017 ... ... specializing in epigenetic research products enables researchers to pursue the recent RNA methylation ... RNA methylation . In light of the newfound characteristics of N6-methyladenosine, or ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... According to ... prostate cancer, including all stages, is more than 95%. Once the cancer spreads to ... less than 30%. To find out how to avoid this latter group, tune in ...
(Date:3/27/2017)... ... March 27, 2017 , ... ?Grow Healthy Vending LLC announced ... litigation between itself and 1800 Vending DBA Healthy You Vending. (Civil No. 1:14-CV-00121-CW/ ... to announce that we have now reached a settlement agreement regarding the ongoing ...
(Date:3/27/2017)... ... March 27, 2017 , ... Harris Communications, Inc., a leading provider of ... latest products to the Deaf Seniors of America Conference, April 4-7 at the Hotel ... with knowledgeable ASL friendly staff from Harris Communications and to try out the newest ...
Breaking Medicine News(10 mins):